Synthesis and antituberculosis activity of novel mefloquine-isoxazole carboxylic esters as prodrugs.

[1]  Trends in tuberculosis--United States, 2007. , 2008, MMWR. Morbidity and mortality weekly report.

[2]  A. Kozikowski,et al.  Design, Synthesis, and Pharmacological Evaluation of Mefloquine‐Based Ligands as Novel Antituberculosis Agents , 2007, ChemMedChem.

[3]  A. Kozikowski,et al.  HTS, Chemical Hybridization, and Drug Design Identify a Chemically Unique Antituberculosis Agent–Coupling Serendipity and Rational Approaches to Drug Discovery , 2007, ChemMedChem.

[4]  S. Franzblau,et al.  Low-Oxygen-Recovery Assay for High-Throughput Screening of Compounds against Nonreplicating Mycobacterium tuberculosis , 2007, Antimicrobial Agents and Chemotherapy.

[5]  Ying Zhang,et al.  Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro. , 2006, The Journal of antimicrobial chemotherapy.

[6]  A. Kozikowski,et al.  Design, Synthesis, and SAR Studies of Mefloquine‐Based Ligands as Potential Antituberculosis Agents , 2006, ChemMedChem.

[7]  Ying Zhang,et al.  Susceptibility of Mycobacterium tuberculosis to weak acids. , 2003, The Journal of antimicrobial chemotherapy.

[8]  Ying Zhang,et al.  Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. , 2002, Journal of Medical Microbiology.

[9]  C. Crabb.  Global Alliance at full steam for new TB drugs. , 2002, Bulletin of the World Health Organization.

[10]  H. Nikaido,et al.  Role of Acid pH and Deficient Efflux of Pyrazinoic Acid in Unique Susceptibility of Mycobacterium tuberculosis to Pyrazinamide , 1999, Journal of bacteriology.

[11]  L. Collins,et al.  Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium , 1997, Antimicrobial agents and chemotherapy.